-
公开(公告)号：US20090004190A1
公开(公告)日：2009-01-01
申请号：US12162658
申请日：2007-01-23
IPC分类号： A61K39/395 , A61P37/00
CPC分类号： C07K14/70503 , A61B5/0059 , A61B5/4088 , A61B5/412 , A61B5/413 , C07K2319/30 , C07K2319/32 , C07K2319/70 , G01J3/4412 , G01N21/4795 , G01N2021/638 , G01N2800/042 , G01N2800/387
摘要： Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
摘要翻译： 公开了包含与第二非RAGE多肽连接的RAGE多肽序列的RAGE融合蛋白。 RAGE融合蛋白可以利用包含RAGE配体结合位点和直接连接到免疫球蛋白CH2结构域的域间连接体的RAGE多肽结构域。 这样的融合蛋白可以提供与RAGE配体的特异的高亲和力结合。 还公开了RAGE融合蛋白作为RAGE介导的病理学的治疗剂的用途。
-
公开(公告)号：US20110282035A1
公开(公告)日：2011-11-17
申请号：US13158748
申请日：2011-06-13
CPC分类号： C07K14/70503 , A61K38/00 , C07K2319/30 , C12N15/62
摘要： Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to the N-terminus of an immunoglobulin CH2 domain. Also disclosed are RAGE fusion protein formulations and the use of the RAGE fusion proteins and RAGE fusion protein formulations as therapeutics for RAGE-mediated pathologies.
摘要翻译： 公开了包含与第二非RAGE多肽连接的RAGE多肽序列的RAGE融合蛋白。 RAGE融合蛋白可以利用包含RAGE配体结合位点的RAGE多肽结构域和直接连接到免疫球蛋白CH2结构域的N末端的域间连接。 还公开了RAGE融合蛋白制剂以及使用RAGE融合蛋白和RAGE融合蛋白制剂作为RAGE介导的病理学的治疗剂。
-
公开(公告)号：US20090060925A1
公开(公告)日：2009-03-05
申请号：US11630916
申请日：2005-08-03
申请人： Adnan M.M. Mjalli , Ye Edward Tian , Jeffrey C. Webster , Robert Rothlein , David M. Stern , Ann Marie Schmidt , Shi Du Yan
发明人： Adnan M.M. Mjalli , Ye Edward Tian , Jeffrey C. Webster , Robert Rothlein , David M. Stern , Ann Marie Schmidt , Shi Du Yan
IPC分类号： A61K39/395 , C07K14/00 , C07K16/00 , C12N15/63 , A61P3/10 , A61P25/28 , A61P29/00 , A61P13/12 , A61P35/00 , A61P9/00 , G01N33/53 , C07H21/00 , A61K38/16
CPC分类号： C07K16/2803 , A61K38/00 , C07K14/705 , C07K2319/30 , G01N33/6893 , G01N33/6896 , G01N2500/00 , G01N2800/042
摘要： Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
摘要翻译： 公开了包含与第二非RAGE多肽连接的RAGE多肽序列的RAGE融合蛋白。 RAGE融合蛋白可以利用包含RAGE配体结合位点和直接连接到免疫球蛋白CH2结构域的域间连接体的RAGE多肽结构域。 这样的融合蛋白可以提供与RAGE配体的特异的高亲和力结合。 还公开了RAGE融合蛋白作为RAGE介导的病理学的治疗剂的用途。
-
公开(公告)号：US20110124102A1
公开(公告)日：2011-05-26
申请号：US12986602
申请日：2011-01-07
CPC分类号： C07K14/705 , A61K38/00
摘要： Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
摘要翻译： 公开了包含与第二非RAGE多肽连接的RAGE多肽序列的RAGE融合蛋白。 RAGE融合蛋白可以利用包含RAGE配体结合位点和直接连接到免疫球蛋白CH2结构域的域间连接体的RAGE多肽结构域。 这样的融合蛋白可以提供与RAGE配体的特异的高亲和力结合。 还公开了RAGE融合蛋白作为RAGE介导的病理学的治疗剂的用途。
-
公开(公告)号：US20110110945A1
公开(公告)日：2011-05-12
申请号：US12899073
申请日：2010-10-06
IPC分类号： A61K39/395 , C07K16/00 , A61P43/00
CPC分类号： C12N15/62 , C07K2319/30
摘要： Disclosed are immunoglobulin fusion proteins and methods of making such proteins. In certain embodiments, the fusion protein may include a non-immunoglobulin polypeptide linked to an immunoglobulin polypeptide. In certain embodiments, the non-immunoglobulin polypeptide may comprise a region that replaces an immunoglobulin Fc hinge region, but that allows for correct assembly of the immunoglobulin chains.
摘要翻译： 公开了免疫球蛋白融合蛋白和制备这些蛋白质的方法。 在某些实施方案中，融合蛋白可包括与免疫球蛋白多肽连接的非免疫球蛋白多肽。 在某些实施方案中，非免疫球蛋白多肽可以包含替代免疫球蛋白Fc铰链区但允许免疫球蛋白链的正确装配的区域。
-
公开(公告)号：US20110244516A1
公开(公告)日：2011-10-06
申请号：US13029622
申请日：2011-02-17
CPC分类号： C07K14/705 , A61K38/00
摘要： Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
-
公开(公告)号：US20110092553A1
公开(公告)日：2011-04-21
申请号：US12950967
申请日：2010-11-19
申请人： Adnan M.M. Mjalli , Dharma R. Polisetti , Govindan Subramanian , James C. Quada, JR. , Murty N. Arimilli , Ravindra R. Yarragunta , Robert C. Andrews , Rongyuan Xie
发明人： Adnan M.M. Mjalli , Dharma R. Polisetti , Govindan Subramanian , James C. Quada, JR. , Murty N. Arimilli , Ravindra R. Yarragunta , Robert C. Andrews , Rongyuan Xie
IPC分类号： A61K31/433 , C07D233/64 , C07D403/10 , C07D285/06 , A61K31/4164 , A61K31/4178 , A61K31/417 , A61P3/10 , A61P35/00 , A61P3/04 , A61P37/00
CPC分类号： C07D233/64 , C07D401/12 , C07D403/10 , C07D409/10 , C07D413/10 , C07D417/10 , C07D417/14
摘要： The present invention provides azole derivatives of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I), and their use in treating human or animal disorders. The compounds of the invention can be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.
摘要翻译： 本发明提供式（I）的唑衍生物，其制备方法，包含式（I）化合物的药物组合物及其在治疗人或动物疾病中的用途。 本发明的化合物可用作蛋白酪氨酸磷酸酶的抑制剂，因此可用于由PTPase活性介导的疾病的治疗，治疗，控制或辅助治疗。 这些疾病包括I型糖尿病和II型糖尿病。
-
公开(公告)号：US20100286197A1
公开(公告)日：2010-11-11
申请号：US12839877
申请日：2010-07-20
IPC分类号： A61K31/472 , A61P3/10 , A61P9/10 , A61P13/12 , A61K31/167 , A61K31/27 , A61K31/351 , A61K31/401 , A61K31/4174 , A61K31/4465
CPC分类号： C07D231/12 , C07C235/38 , C07C237/20 , C07C271/22 , C07C2601/08 , C07C2603/18 , C07D207/16 , C07D211/34 , C07D217/26 , C07D233/56 , C07D249/08 , C07D309/04
摘要： This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
摘要翻译： 本发明提供某些化合物，其制备方法，包含该化合物的药物组合物及其在治疗人或动物疾病中的用途。 本发明的化合物可用作晚期糖基化终产物（RAGE）的受体与其配体如晚期糖基化终产物（AGE），S100 /钙粒蛋白/ EN-RAGE，淀粉样蛋白和 两性霉素，以及由RAGE引起的人类疾病的管理，治疗，控制或辅助治疗。 这些疾病或疾病状态包括急性和慢性炎症，糖尿病晚期并发症的发展，例如血管通透性增加，肾病，动脉粥样硬化和视网膜病变，阿尔茨海默病的发展，勃起功能障碍和肿瘤侵袭和转移。
-
公开(公告)号：US20090306063A1
公开(公告)日：2009-12-10
申请号：US12399504
申请日：2009-03-06
申请人： Adnan M.M. Mjalli , Dharma Rao Polisetti , Thomas Scott Yokum , Kalpathy Santhosh , Mustafa Guzel , Christopher Behme , Stephen Thomas Davis
发明人： Adnan M.M. Mjalli , Dharma Rao Polisetti , Thomas Scott Yokum , Kalpathy Santhosh , Mustafa Guzel , Christopher Behme , Stephen Thomas Davis
IPC分类号： A61K31/5365 , C07D265/34 , A61P3/10
CPC分类号： C07D498/04 , C07D498/14
摘要： The present invention provides oxadiazoanthracene derivatives of the formula (I), wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, pharmaceutical compositions comprising oxadiazoanthracene derivatives, use of the oxadiazoanthracene derivatives for the preparation of pharmaceutical compositions, methods of use thereof for the treatment and/or prevention of disorders and diseases, such as diabetes, and intermediates useful for the preparation of oxadiazoanthracene derivatives of Formula (I).
摘要翻译： 本发明提供式（I）的恶二唑并蒽衍生物，其中A，B，C，R，R 1，R 2，R 3，R 4和R 5如本文所述，包含恶二唑并蒽衍生物的药物组合物，使用恶二唑衍生物用于制备 的药物组合物，其用于治疗和/或预防疾病和疾病的方法，例如糖尿病，以及可用于制备式（I）的恶二唑衍生物的中间体。
-
10.发明申请USE OF METFORMIN IN COMBINATION WITH A GLUCOKINASE ACTIVATOR AND COMPOSITIONS COMPRISING METFORMIN AND A GLUCOKINASE ACTIVATOR 有权麦角蛋白与GLUCOKINASE激活剂的组合和包含甲羟孕酮和GLUCOKINASE激活剂的组合物的使用公开(公告)号：US20110313007A1
公开(公告)日：2011-12-22
申请号：US13114964
申请日：2011-05-24
IPC分类号： A61K31/426 , A61P3/10 , A61P3/08 , C07D277/54
CPC分类号： A61K31/426 , A61K31/155 , C07D277/54
摘要： The present invention provides uses of a glucokinase activator in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, improving insulin sensitivity, enhancing phosphorylation of glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GK activator and metformin. The invention also provides a salt formed between metformin and a GK activator.
摘要翻译： 本发明提供葡糖激酶活化剂与二甲双胍组合的用途。 用途包括治疗2型糖尿病，降低血糖，改善胰岛素敏感性，增强葡萄糖磷酸化，提高二甲双胍的治疗效果。 本发明还提供包含GK活化剂和二甲双胍的药物组合物。 本发明还提供了在二甲双胍和GK活化剂之间形成的盐。
-
-
-
-
-
-
-
-
-
搜索结果
28 条记录 (耗时 0.034 秒)